Korro Bio, INC

Korro Bio reported Q2 2026 results, highlighting progress on KRRO-121 and KRRO-111, receiving EMA Orphan Drug Designation, and maintaining a cash runway into late 2028.

Korro Bio stockholders elected two Class I directors, approved executive compensation, and ratified the appointment of Ernst & Young LLP.

Korro Bio announces KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency, showing promising preclinical results in restoring functional AAT protein.

Korro Bio announced first quarter 2026 financial results, highlighting significant scientific progress in its RNA editing platform and a corporate update including an $85 million private placement.

Korro Bio announced its full year 2025 financial results, highlighted by the nomination of a new development candidate KRRO-121 and an oversubscribed $85 million private placement extending its cash runway into the second half of 2028.

Korro Bio presented preclinical data for KRRO-121, a potential first-in-class treatment for hyperammonemia in Urea Cycle Disorders and Hepatic Encephalopathy, at its virtual Analyst Day.

Korro Bio, Inc. (KRRO) filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing operating losses and strategic adjustments, including workforce reductions and the termination of a clinical trial.

Korro Bio, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $19.6 million and a cash runway extending into the second half of 2028 following a significant private placement.

Korro Bio reported a widened net loss in Q3 2025, announced a pivot for its AATD program after KRRO-110 failed to meet protein targets, and paused its collaboration with Novo Nordisk.

Korro Bio, a clinical-stage biopharmaceutical company, reported increased net losses and cash burn for the first half of 2025, despite initiating collaboration revenue and advancing its lead RNA editing program, KRRO-110, into Phase 1/2a clinical trials.

Korro Bio, a clinical-stage biopharmaceutical company, announced its first quarter 2025 financial results, highlighting progress in its AATD clinical program and strategic streamlining efforts.

Korro Bio, a biopharmaceutical company focused on RNA editing, reported its third quarter 2024 financial results, highlighting a collaboration with Novo Nordisk and progress in its clinical programs.

Korro Bio reports significant losses and a strategic shift in its AATD program after a clinical setback, while advancing its hyperammonemia candidate and securing new funding.

Korro Bio advances its RNA editing platform with clinical trial initiation and pipeline development, while reporting a net loss for 2024.

Korro Bio's 10-K filing details its RNA editing platform, OPERA, and its pipeline of therapeutic programs targeting various diseases.

Jean Francois Formela, a Director of Korro Bio, Inc., sold 2,143 shares of common stock on August 11, 2026 for $13.96 per share.

Lynx1 Capital Management LP and 1 other reported changes in beneficial ownership of Korro Bio, Inc. common stock on August 6, 2026.

Loic A Vincent, Chief Scientific Officer of Korro Bio, Inc., received 7,500 shares of common stock on July 15, 2026.

Oliver Dolan, Senior Vice President, Finance of Korro Bio, Inc., received 5,500 shares of common stock on July 15, 2026.

Jeffrey Cerio, General Counsel of Korro Bio, Inc., received 6,500 shares of common stock on July 15, 2026.

Todd Chappell, Chief Operating Officer of Korro Bio, Inc., received 7,500 shares of common stock on July 15, 2026.

Korro Bio, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting of stockholders to be held virtually on June 10, 2026.

Korro Bio, Inc. will hold its annual meeting of stockholders on June 11, 2025, with online access details and voting information now available.

Korro Bio, Inc. announces its 2025 annual meeting of stockholders to be held virtually on June 11, 2025, featuring proposals including director elections, executive compensation approval, and auditor ratification.

Korro Bio, Inc. will hold its 2024 annual meeting of stockholders virtually on June 11, 2024, to vote on director elections, an amendment to the Restated Certificate of Incorporation, and ratification of the company's independent auditor.

Korro Bio, Inc. will hold its annual meeting of stockholders on June 11, 2024, to elect directors, approve an amendment to limit officer liability, and ratify the appointment of Ernst & Young LLP as its independent auditor.

Korro Bio's upcoming annual meeting on June 11, 2024, will address the election of directors, an amendment to limit officer liability, and the ratification of Ernst & Young LLP as the company's auditor.

Korro Bio is registering the resale of up to 1,213,569 shares of its common stock by selling stockholders, with the company not receiving any proceeds from the sale.

Korro Bio, Inc. has filed an amendment to its Schedule 13D, detailing significant transactions in its common stock by major holders Atlas XI and AVOF II over the past sixty days.

New Enterprise Associates 17, L.P. and its affiliates increased their beneficial ownership in Korro Bio, Inc. to 9.9% through a recent private placement.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 951,783 shares, representing 6.6% of Korro Bio, Inc.'s common stock.

Point72 Asset Management and affiliated entities have reported a 1.9% beneficial ownership stake in Korro Bio, Inc. as of March 31, 2026.

Lynx1 Capital Management LP and Weston Nichols have reported a 10.7% beneficial ownership stake in Korro Bio, Inc.

The Vanguard Group filed an amended Schedule 13G, indicating zero beneficial ownership in Korro Bio Inc. following an internal realignment effective January 12, 2026.

A group of Venrock entities and individuals have disclosed a 9.9% beneficial ownership stake in Korro Bio, Inc. through a Schedule 13G filing.

Driehaus Capital Management LLC has filed an exit notice, reporting zero beneficial ownership in Korro Bio, Inc. common stock.